Université Catholique de Louvain (UCL-Bruxelles)
Programme des Séminaires et Conférences du
Louvain Drug Research Institute et de l'Ecole doctorale en sciences pharmaceutiques
Année académique 2009-2010

10.30 Bernard Gallez (UCLouvain)
Welcome

10.35. M.A. Tarpan (Ugent)
Electron magnetic resonance study of primary free radicals in trehalose single crystals

11.00 Y. Ling (University of Antwerpen)
EPR investigation of cationic radicals for organic electronic applications

11.25 J. Leprince (UCLouvain)
Contribution of EPR technology to the study of dental resins

11.50. G. Mathies (University of Leiden)
CW EPR on Fe(III)-EDTA and Fe(III)-rubredoxin at 275 GHz using a single-mode cavity

12.15-13.00 Lunch (Buffet)

13.00-13.45 Poster Session

13.45 P.Y. Frapart (Université Paris-Descartes)
Taking care of metabolism in EPR in vivo imaging, a trithyl radical EPR study in mice articulation merged with X-Ray Micro CT

14.10 P.H. Guelluy (University of Liège)
Multiple spectroscopic study of in vitro photodynamic therapy induced by PPME

14.35 M. Ezhevskaya (University of Antwerpen)
B10 Phenylalanine plays a key role in neuroglobin

15.00 Coffee/Tea Break

15.20 KAP.Wijnands (University of Maastricht)
Intracellular NO metabolism by ESR and influence on endothelial dysfunction in a prolonged murine endotoxemia model

15.35 M. Huber (University of Leiden)
Distances between paramagnetic metal centers and spin labels in proteins by pulsed EPR: The RIDME method as a new tool.

16.00 APD Nguyen (KULeuven)
Point defects at the epitaxial Ge3N4/(111)Ge interface studied by electron spin resonance

16.25 General Assembly / Closing Remarks

16.35 Farewell drink

info : B. Gallez 02/764.73.91 <bernard.gallez@uclouvain.be>

Dr Tatiany Faria
Laboratory of Immunology and Infectious Diseases, Department of Microbiology and Parasitology (MIP),
Center of Biological Sciences (CCB)
Federal University of Santa Catarina (UFSC), Florianópolis, Brazil

Nano-enabled drug delivery of the isoniazid citral-derivative JVA001 enhances Mycobacterium tuberculosis intracellular killing

info : P. Tulkens 02.764.73.71<Tulkens@facm.ucl.ac.be>

16h30 : Welcome (coffee / tea)
17h00 : P.M. Tulkens (UCL) : introduction
17h05 : C. LipinskiMelior Discovery, Waterford, CT : Rules, filters, pharmaceutical principles and future trends in drug discovery
18h00 : P. ChaltinCentre for Drug Design and Discovery (CD3), KU-Leuven : CD3, the investment fund for innovative early-stage drug discovery in Belgium
18h30 : Open Discussion (moderated by J. Poupaert)
19h00 : Reception

info : P. Tulkens 02.764.73.71<tulkens@facm.ucl.ac.be>

Prof. Sophie Sarre
Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information
Research group Experimental Neuropharmacology,
Vrije Universiteit Brussel

Neuroprotective strategies in animal models of Parkinson’s disease and stroke

publications en relation avec l'exposé:

• Yuan et al. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res. 2004 Nov 5;1026(1):95-107.
• Van Hemelrijck et al. Post-ischaemic mild hypothermia inhibits apoptosis in the penumbral region by reducing neuronal nitric oxide synthase activity and thereby preventing endothelin-1-induced hydroxyl radical formation. Eur J Neurosci. 2005 Sep;22(6):1327-37.
  
• Mertens et al. Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat.Neuroscience. 2009 Aug 4;162(1):148-54.

info : D. Lambert 02.764.73.47 <didier.lambert@uclouvain.be>

Dr. Patrice Cani
Nutrition and Metabolism research group, LDRI, Université catholique de Louvain

Mécanismes physiopathologiques impliqués dans le développement de l'inflammation associés à l’obésité et au diabète de type 2 : impact du microbiote intestinal

publications en relation avec l'exposé:

• Cani et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009 Aug;58(8):1091-103.
• Cani et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008 Jun;57(6):1470-81.
• Cani PD, et al. Current Opinion in Pharmacology 2009 Jul 21. [Epub ahead of print]

info : N. Delzenne 02.764.73.67 <nathalie.delzenne@uclouvain.be>

Laure Bindels
Nutrition and Metabolism research group, LDRI

Control of cachexia associated with tumor development : role of the gut microbiota

Mesures de l'étendue de mélanomes cutanés et de métastases pulmonaires: comparaison entre la résonance paramagnétique électronique (R.P.E.) et l'imagerie par bioluminescence (B.L.I.)

Prof. A. Van Aerschot
Rega Institute, Medicinal Chemistry, K.U.Leuven

The therapeutic potential of antisense and siRNA strategies

publications en relation avec l'exposé:

• Fisher et al. Inhibition of MDR1 expression with altritol modified siRNAs. Nucleic Acids Res. (2007) 35, 1064-1074.
• Fisher et al. Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. European J Pharmacol (2009) 606, 38-44 .
• EU consortium. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity Nucleic Acids Res., (2009) 37, 2867-2881.
• Kortylewski et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotechnology, Published online: 13 September 2009 | doi:10.1038/nbt.1564
  

info : F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

Prof. M. Raes
Unité de Recherche en Biologie Cellulaire, FUNDP

Comparative study of copper- and myeloperoxidase-oxidized LDL- Effects on Nrf2 activation in cultured macrophages and endothelial cells

info : P. Tulkens 02.764.73.71<paul.tulkens@uclouvain.be>

Mireille Al Houayek,
Unité de chimie pharmaceutique et unité de chimie analytique et pharmacognosie, LDRI

Etude du rôle potentiel de récepteur GPR55 dans l'inflammation

info: G. Muccioli 02.764.72.31 <giulio.muccioli@uclouvain.be>

Profs R. Rezsohazy et B. Feltz
Unité des sciences vétérinaires et Logique et philosophie des sciences, UCL

14h30: DARWIN et la science contemporaine. Regards croisés du scientifique et du philosophe.
16h30: visite de la galerie de l'évolution
18h30: dîner pour ceux qui le souhaitent

Inscription obligatoire (nombre de places limité dans l'auditorium)

plus d'information sur le site web de PharmaLouvain (http://www.md.ucl.ac.be/pharmalouvain/)

info :J. Hanot 02.762.10.38 <jacques.hanot@skynet.be>

Prof. E. Hermans
Unité de Pharmacologie expériementale, UCL

Comment réaliser un bon Journal Club ?

info : B. Gallez 02.764.73.91 <Bernard.Gallez@uclouvain.be>

Collection pharmaceutique Albert Couvreur : Visites guidées par petits groupes

Présentation à 17 h 30 en français et à 19 h en néerlandais, sur le thème : De la Plante au Médicament, une Odyssée.

Entrée : 2,50 euros ; gratuit pour les étudiants.

info: N. Marcelle <nicole.marcelle@skynet.be>

Dr S. De Smedt
Laboratory of General Biochemistry and Physical Pharmacy,University of Ghent

Towards a better understanding of the extra- and intracellular behavior of nanosized matter

Publications en lien avec l'exposé

• Lentacker et al, Ultrasound exposure of lipoplex loaded microbubbles facilitates direct cytoplasmic entry of the lipoplexes. Mol Pharm. 2009 6(2):457-67.
• Soenen et al. Stable long-term intracellular labelling with fluorescently tagged cationic magnetoliposomes. Chembiochem. 2009 Jan 26;10(2):257-67.

info : V. Préat 02.764.73.09 <Veronique.Preat@uclouvain.be>

Dr K. Faure
EA 2689, IFR 114, Faculté de Médecine, Université de Lille 2 and CHRU de Lille, Lille, France

Physiopathologie de la pneumonie à Pseudomonas aeruginosa: nouvelles cibles thérapeutiques

info :F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

12h45 - 13h30 : Accueil et sandwichs
13h30 - 14h : Bertrand Bearzatto (équipe de JL Gala) : Outils de modélisation et de validation des applications biomédicales dans le domaine des nouveaux biomatériaux.
14h - 14h30 : Denis Dufrane et Catherine Behets : Potentiel des cellules souches adipeuses en reconstruction osseuse.
14h30 - 15h : Yves-Jacques Schneider : Biomatériaux et systèmes de culture cellulaire.
15h - 15h30 : Discussion et planification des prochaines séances.

Inscription aux sandwichs et/ou au séminaire par Email : Sophie Demoustier (EPL) - Christine Dupont (AGRO) - Gaëtane Leloup (MD)

Prof. Peter W. Taylor
Department of Pharmaceutics
School of Pharmacy
University of London, London, UK

Some new approaches to the treatment of bacterial Infections

Publications en lien avec l'exposé

• Stapleton et al. 2007. The beta-lactam-resistance modifier (-)-epicatehin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology 153:2093-2103.
• Zelmer et al. 2008. Differential expression of the polysialyl capsule during blood-to-brain transit of neuropathogenic Escherichia coli K1. Microbiology 154:2522-2532.
• Bernal et al. 2009. Disruption of D-alanyl esterification of Staphylococcus aureus cell wall teichoic acid by the beta-lactam-resistance modifier (-)-epicatechin gallate. Journal of Antimicrobial Chemotherapy 63:1156-1162.
  

info :F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

publications en relation avec l'exposé:

• Vásquez et al. Synthesis and antitumor evaluation of 8-phenylamino-pyrimido[4,5-c]isoquinolinequinones. Bioorg. Med. Chem. Lett. 2009, 19, 5060-2.
• Valderrama et al. Studies on quinones. Part 44: Novel angucyclinone N-heterocyclic analogues endowed with antitumoral activity. Bioorg. Med. Chem. 2008, 16, 10172-81.
• Valderrama and Vasquez. Design and synthesis of angucyclinone AB-pyrido[2,3-d]pyrimidine analogues. Tetrahedron Lett. 2008, 49, 703-6.
  

Philippe Monteyne, MD, PhD
Senior Vice President
Head of Global Vaccine Development
GlaxoSmithKline Biologicals

Vaccin H1N1: expérience actuelle

info :F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>
et Emmanuel Hermans 02/764.93.39 <emmanuel.hermans@uclouvain.be>

Laetitia Garcia,
Unité de pharmacologie cellulaire et moléculaire, LDRI

Data Club : Accumulation cellulaire et activité des antibiotiques sur Staphylococcus aureus (et ses formes Small Colony Variants) dans des modèles in vitro de mucoviscidose

Barbara Sneyers
centre de pharmacie clinique, UCL

Journal club: Treggiari, et al., Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med, 2009. 37(9): p. 2527-34

publications en relation avec l'exposé:

• Labar et al. Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem. 2007 Jul 23;8(11):1293-7.PMID: 17579916
• Labar et al. A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison. Amino Acids. 2008 Jan;34(1):127-33.PMID: 17476568
• Labar et al. Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling. Chembiochem. 2009 - Epub- PMID: 19957260
  

Prof. J. Van Beeumen
Department of Biochemistry and Microbiology, Laboratory for Protein Biochemistry and Biomolecular Engineering, University Ghent

Role of protein(s) in the formation of biofilms: studies with the bacterial species Shewanella

publications en relation avec l'exposé:

• Theunissen et al. The 285 kDa Bap/RTX hybrid cell surface protein (SO4317) of Shewanella oneidensis MR-1 is a key mediator of biofilm formation.Res Microbiol. 2009 Dec 21. [Epub ahead of print]
• De Vriendt et al. Proteomics of Shewanella oneidensis MR-1 biofilm reveals differentially expressed proteins, including AggA and RibB. Proteomics. 2005 Apr;5(5):1308-16.PMID: 15712242

info : P. Tulkens 02.764.73.71<Tulkens@facm.ucl.ac.be>

publications en relation avec l'exposé:

• Van de Velde et al. Contrasting effects of human THP-1 cells differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
  Journal of Antimicrobial Chemotherapy (2008) 62:518-521 PMID=18544595
• Van de Velde et al. Penicillin-binding Proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in beta-lactam sensitivity of Listeria monocytogenes. Gut Pathogens (2009) 1:23 PMID=20003484
• Van de Velde et al. Isolation and 2D-DIGE proteomic analysis of intracellular and extracellular forms of Listeria monocytogenes. Proteomics (2009) 9:5484-5496 PMID=19834917
  

publications en relation avec l'exposé:

• Daneau et al. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases. Clin Cancer Res. 2010 Jan 15;16(2):410-9. Epub 2010 Jan 12 PMID: 20068092
  

Dr. Marlène Dubuisson
Conseiller technologique Biotech Santé MIRVAL - Académie Louvain
ADRE, Université catholique de Louvain

Projet Mirval (MIse en Réseau de la VALorisation): propriété intellectuelle et valorisation de la recherche

info : V. Préat 02.764.73.09 <Veronique.Preat@uclouvain.be>

Dr. Julien Verrax
Unité de pharmacocinétique, métabolisme, toxicologie et nutrition, LDRI, Université catholique de Louvain

Exploiting cancer cell redox status to optimize cancer therapy

publications en relation avec l'exposé:

• Verrax et al. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Current Medicinal Chemistry, 2009, 16, 1821-1830.
• Trachootham et al. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery, 2009, 8, 579-591.

info: P. Buc Calderon 02.764.73.66 <pedro.buccalderon@uclouvain.be>

• 13h30 : Pharmacovigilance : fiche jaune, de la perte de temps à l’utilité réelle
  Animateur : Phcienne V. Lacour (SSPF). Modérateur : Dr Baeyens (SSMG)
• 14h30 : Le parcours de l’ordonnance : du prescripteur à Pharmanet
  Animateur : Phcien L. Vansnick (APB). Modérateur : Dr Vanhalewyn (SSMG)
• 15h30 : Des modèles de collaboration médecins-pharmaciens
  - Le projet Diabetest - Dr Pizzuto (SSMG)
  - La fiche de posologie – Phcien A. Chaspierre (SSPF)
  - Les trajets de soins – Phcien C. Elsen (APB)
  Modérateur : Dr Beuken (SSMG)

info et inscription (gratuite mais obligatoire): SSPF <sspf@sspf.be> / programme et formulaire d'inscription

Prof. John C. Waterton
Biomedical Imaging Institute
School of Cancer & Imaging Sciences, Faculty of Medicine & Human Sciences
University of Manchester, UK

Imaging Biomarkers in Drug Development

info : B. Gallez 02.764.73.91 <Bernard.Gallez@uclouvain.be>

Prof. Jean-Christophe Jonas
Institut de Recherche Expérimentale et Clinique (IREC), Groupe de recherche en Endocrinologie, Diabète et Nutrition; Université catholique de Louvain

Glucose regulation of pancreatic islet stress responses

Publication en lien avec l'exposé

• Jonas et al. Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. Diabetes Obes Metab. 2009 11 Suppl 4:65-81

info :F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

Gaetane Behets Wydemans
Groupe Cardiovasculaire du Pôle de Pharmacologie et Thérapeutique (IREC)

Dr J. Bulitta,
Ordway Research Laboratories,
Albany, NY

(Speaker already in Europe ...)

Combination therapy of P. aeruginosa with special reference to modeling of polymyxins in vitro and to preliminary animal models

followed by an educational demonstration on Monte Carlo simulations for anti-infectives

Publications en lien avec l'exposé

• Bulitta et al. High Inoculum Pseudomonas aeruginosa Attenuates Colistin Bactericidal Activity Characterized by a New Mechanism-based Population Pharmacodynamic Model. Antimicrob Agents Chemother. 2010 Mar 8.PMID: 20211900
• Bulitta et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010 Mar;54(3):1275-82. PMID: 20065059
  

info : P. Tulkens 02.764.73.71 <paul.tulkens@uclouvain.be>

J. Blondeau,
Department of Clinical Microbiology, Royal University Hospital, Canada

(to be confirmed ...
Speaker still in Canada ...)

The "Mutant Prevention Concentration" or how to prevent or mitigate resistance with fluoroquinolone antibiotics

Publications en lien avec l'exposé

• Blondeau. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol. 2009 Oct;20(5-6):383-96.
• Blondeau et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother. 2004 Jun;16 Suppl 3:1-19.
  

info : P. Tulkens 02.764.73.71 <paul.tulkens@uclouvain.be>

publications en relation avec l'exposé:

• Capron A et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit. 2007 Jun;29(3):340-8.PMID: 17529892
• Capron A et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit. 2009 Apr;31(2):178-86.PMID: 19057467
  

Prof. Jean-Michel Scherrmann
Department of Pharmaceutical Sciences
and Neuropsychopharmacology on Drug Addiction Unit, University Paris Descartes, France

Diversity of Transport and Metabolism Processes in the Blood-Brain Barrier

Publications en lien avec l'exposé

• André et al. Clonidine transport at the mouse blood-brain barrier by a new H+ antiporter that interacts with addictive drugs. J Cereb Blood Flow Metab. (2009) 29(7):1293-1304.
• Dauchy et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem. (2008) 107(6):1518-1528.
  

info :F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

Gaetane Behets Wydemans,
Groupe Cardiovasculaire du Pôle de Pharmacologie et Thérapeutique (IREC)

Hayet Bensikaddour,
Pharmacologie cellulaire et moléculaire, LDRI

Edith Staes,
Pharmaceutics research group, LDRI

Salome Koussoroplis,
Pharmaceutics Research group (LDRI)

Prof. Guillermo Velasco
Complutense University
Department of Biochemistry and Molecular Biology, School of Biology
Madrid, Spain

Cannabinoid antitumoral action: inducing ER stress and autophagy to promote cancer cell death

Publications en lien avec l'exposé

• Carracedo et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.
  Cancer Cell 9, 301-312 (2006)
• Salazar et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119:1359-1372 (2009)
  

info :P. Buc Caderon 02.764.73.66 <pedro.buccalderon@uclouvain.be>

Dr Malcolm Page
Head of Biology
Basilea Pharmaceutica, Basel, Switzerland

Novel inhibitors of class C beta-lactamases: from the chemical lab to clinical evaluation

Publications en lien avec l'exposé

• Page et al. In-vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multi-resistant Gram-negative Bacilli. Antimicrob Agents Chemother. 2010 Mar 22. [Epub ahead of print] PMID: 20308379
  

info : P. Tulkens 02.764.73.71<Tulkens@facm.ucl.ac.be>

12h45-13h00: Welcome + Introduction
13h00-13h20: GC-2010 plus - High performance & flexible instrument
13h20-13h40: QP-2010 plus - High Specification Instrument
13h40-14h00: Pause
14h00-14h10: Introduction to MDGC
14h10-15h00: Introduction to Comprehensive GC (Multidimentionnal GC)
Application “Environmental” + “Human” (Prof. J-F. Focant ­ Ulg/CART)

Renseignements : Jean-Louis Habib Jiwan (02/764 73 68 - j-l.habib@uclouvain.be) et Marie-France Hérent (02/764 72 32 - marie-france.herent@uclouvain.be)

inscription: olivier.davidts@shimadzu.be

Former des pharmaciens acteurs de santé publique en 2010

info : F. Van Bambeke 02.764.73.78 <francoise.vanbambeke@uclouvain.be>

Prof. Didier Cataldo
GIGA-Research,
Université de Liège et CHU Liège

Les métalloprotéases matricielles sont-elles des cibles thérapeutiques dans les maladies respiratoires obstructives ?

publications en relation avec l'exposé:

• Paulissen et al. Role of ADAM and ADAMTS metalloproteinases in airway diseases. Respir Res. 2009 Dec 24;10:127.
• Garbacki et al. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther. 2009 Aug;22(4):267-78.

info : R. Vanbever 02.764.73.25 <Rita.vanbever@uclouvain.be>